You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

42 search results for: mechanism of disease

videoanimation

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

4 min

Pulmonology

Learn about the significant burden that patients with COPD experience and the role of inflammatory mechanisms in this chronic, often progressive disease.

<b>Mechanism</b>s <b>of</b> Pruritus in AD & PN: Role <b>of</b> Type 2 Inflammation

expert video

Mechanisms of Pruritus in AD & PN: Role of Type 2 Inflammation

20 min

Dermatology

Neuroimmune mechanisms of chronic pruritus in atopic dermatitis and prurigo nodularis – Clip from the ADVENT symposium at AAD 2023.

ERS 2023 | The Impact <b>of</b> Type 2 Inflammation on COPD: Examining Its Role in <b>Disease</b> Pathophysiology

expert video

ERS 2023 | The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology

17 min

Pulmonology

Prof. Klaus Rabe and Dr. Stephanie Christenson explore COPD's clinical presentation through disease pathology, emphasizing its diverse inflammatory pathways.

Pathways to <b>Disease</b>: Inflammation in COPD

interactivity

Pathways to Disease: Inflammation in COPD

5 min

Pulmonology

Learn about the pathophysiology of COPD and the involvement of chronic inflammation on the airways

expert video

PN and AD: Distinct Diseases with Underlying Type 2 Inflammation

1 min

Dermatology

Prurigo nodularis (PN) and atopic dermatitis (AD): Distinct diseases with underlying type 2 inflammation – highlights from the ADVENT symposium at AAD 2023.

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

interactivity

COPD and Asthma: What's the Difference and Is There a Link?

5 min

Pulmonology

Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

<b>Disease</b> Modification Concepts in AD

expert video

Disease Modification Concepts in AD

1 min

Type 2 Inflammation

Dr. Ramien explores the concept of disease modification in AD focusing on disease control, and the prevention or slowing of development of atopic comorbidities.

ADVENT On Air | Exploring PN as a Distinct and Unique <b>Disease</b>

audio

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

20 min

Dermatology

Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct <b>Disease</b>s with Shared Characteristics

interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

5 min

Dermatology

Explore our interactive tool showcasing the unique and shared features, burden, and risk factors of atopic dermatitis and prurigo nodularis.

<b>Disease</b>-Specific Aspects <b>of</b> Itch in AD, PN, and CSU

expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

16 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

Chronic Spontaneous Urticaria: <b>Disease</b> Overview

interactivity

Chronic Spontaneous Urticaria: Disease Overview

5 min

Dermatology

Explore CSU: Uncover its clinical features, epidemiology, and its profound impact on patients’ lives in this interactive tool.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region